Schier R, Bye J, Apell G, McCall A, Adams G P, Malmqvist M, Weiner L M, Marks J D
Department of Anesthesia and Pharmaceutical Chemistry, University of California, San Francisco 94110, USA.
J Mol Biol. 1996 Jan 12;255(1):28-43. doi: 10.1006/jmbi.1996.0004.
The use of antibodies to target tumor antigens has had limited success, partially due to the large size of IgG molecules, difficulties in constructing smaller single chain Fv (scFv) antibody fragments, and immunogenicity of murine antibodies. These limitations can be overcome by selecting human scFv directly from non-immune or semi-synthetic phage antibody libraries; however, the affinities are typically too low for therapeutic application. For hapten antigens, higher-affinity scFv can be isolated from phage antibody libraries where the VH and VL genes of a binding scFv are replaced with repertoires of V genes (chain shuffling). The applicability of this approach to protein binding scFv is unknown. For this work, chain shuffling was used to increase the affinity of a non-immune human scFv, which binds the glycoprotein tumor antigen c-erbB-2 with an affinity of 1.6 x 10(-8) M. The affinity of the parental scFv was increased sixfold (Kd = 2.5 x 10(-9) M) by light-chain shuffling and fivefold (Kd = 3.1 x 10(-9) M) by heavy-chain shuffling, values comparable to those for antibodies against the same antigen produced by hybridomas. When selections were performed on antigen immobilized on polystyrene, spontaneously dimerizing scFv were isolated, the best of which had only a slightly lower Kd than wild type (Kd = 1.1 x 10(-8) M). These scFv dimerize on phage and are preferentially selected as a result of increased avidity. Compared to scFv which formed only monomer, dimerizing scFv had mutations located at the VH-VL interface, suggesting that VH-VL complementarity determines the extent of dimerization. Higher-affinity monomeric scFv were only obtained by selecting in solution using limiting concentrations of biotinylated antigen, followed by screening mutant scFv from bacterial periplasm by koff in a BIAcore. Using the proper selection and screening conditions, protein binding human scFv with affinities comparable to murine hybridomas can be produced without immunization.
利用抗体靶向肿瘤抗原的方法取得的成功有限,部分原因在于免疫球蛋白G(IgG)分子体积较大、构建较小的单链Fv(scFv)抗体片段存在困难以及鼠源抗体具有免疫原性。通过直接从非免疫或半合成噬菌体抗体文库中筛选人源scFv可克服这些限制;然而,其亲和力通常过低,无法用于治疗。对于半抗原,可从噬菌体抗体文库中分离出亲和力更高的scFv,其中结合性scFv的重链可变区(VH)和轻链可变区(VL)基因被V基因文库所取代(链改组)。这种方法对蛋白质结合scFv的适用性尚不清楚。在本研究中,采用链改组来提高一种非免疫人源scFv的亲和力,该scFv以1.6×10⁻⁸ M的亲和力结合糖蛋白肿瘤抗原c-erbB-2。通过轻链改组,亲本scFv的亲和力提高了6倍(解离常数Kd = 2.5×10⁻⁹ M),通过重链改组提高了5倍(Kd = 3.1×10⁻⁹ M),这些值与杂交瘤产生的针对相同抗原的抗体相当。当在固定于聚苯乙烯的抗原上进行筛选时,分离出了自发二聚化的scFv,其中最佳者的Kd仅略低于野生型(Kd = 1.1×10⁻⁸ M)。这些scFv在噬菌体上二聚化,并由于亲和力增加而被优先选择。与仅形成单体的scFv相比,二聚化scFv在VH-VL界面处存在突变,这表明VH-VL互补性决定了二聚化程度。只有通过使用有限浓度的生物素化抗原在溶液中进行筛选,然后在BIAcore中通过解离速率筛选来自细菌周质的突变scFv,才能获得亲和力更高的单体scFv。使用合适的筛选和选择条件,无需免疫即可产生亲和力与鼠源杂交瘤相当的蛋白质结合人源scFv。